Merus N.V. is a clinical-stage biotechnology company based in Utrecht, the Netherlands, with operations in the United States. The company develops full-length human bispecific and multispecific antibody therapeutics for oncology, using its proprietary Biclonics and Triclonics platforms to target solid tumors and hematologic malignancies. Merus is listed on Nasdaq under the ticker MRUS.
Key investigational programs include petosemtamab (MCLA-158), an EGFR x LGR5 bispecific antibody evaluated in head and neck and other solid tumors; zenocutuzumab (MCLA-128), a HER2/HER3 bispecific studied particularly in NRG1 fusion–positive cancers; MCLA-129, an EGFR x c-MET bispecific for EGFR- and MET-driven tumors; and MCLA-145, a CD137 x PD-L1 bispecific in immuno-oncology. The company advances these candidates through clinical development and scientific collaborations aimed at improving precision treatment options in cancer.
